Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Retention Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Agios Pharm Retention Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The retention ratio, also known as the plowback ratio, measures the proportion of a company's earnings that are retained after paying dividends. It is calculated by dividing the net income minus dividends paid by the net income. This ratio indicates the percentage of earnings that are reinvested back into the company rather than being distributed to shareholders as dividends. A higher retention ratio suggests a higher level of reinvestment, indicating potential future growth opportunities.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends